- Ozempic Could Help Curb Alcoholism
- AI Helps Spot Brain Tumor Tissue Surgeons Miss
- Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia
- Big Post-Election Surge Seen in Online Sales of Morning-After Pills
- Canadian Teen Hospitalized in Critical Condition With Bird Flu
- Liquor, Wine, Beer: Which Comes With the Worst Lifestyle?
- Fatty Liver Disease Now Affects 4 in 10 U.S. Adults
- Good Night’s Sleep Wards Off High Blood Pressure in Teens
- Telehealth Can Help Prevent Suicide in Those at High Risk
- Most Parents Don’t Ask About Unlocked Guns in Homes Their Kids Visit
Eye Tests Might Help ID Alzheimer’s, Studies Suggest
Eye tests could be used to identify people in the early stages of Alzheimer’s disease, two new studies suggest.
In one study, early results from 40 participants who used a certain eye test found a significant association between levels of beta-amyloid plaques in the retina of the eye and levels of the plaques in the brain. Beta-amyloid plaques in the brain are associated with Alzheimer’s disease.
This type of eye test could be used in conjunction with the brain scans and clinical tests currently relied on to diagnose Alzheimer’s, study author Shaun Frost, of the Commonwealth Scientific and Industrial Research Organization in Australia, said in a news release from the Alzheimer’s Association.
The eye test could also be used to monitor the progression of Alzheimer’s and a patient’s response to treatment, Frost added.
The preliminary results were scheduled for release at the annual meeting of the Alzheimer’s Association in Copenhagen, Denmark, which started Sunday. The full study, involving 200 participants, is expected to be completed later this year.
Another study presented at the meeting utilized a different type of eye test. It found a strong link between levels of beta-amyloid plaques in the lens of the eye and in the brain.
“There is a critical need for a fast, dependable, low-cost and readily available test for the early diagnosis and management of Alzheimer’s disease,” Dr. Pierre Tariot, director of the Banner Alzheimer’s Institute in Phoenix, Ariz., said in an Alzheimer’s Association news release. Tariot was a principal investigator in the study.
Research presented at meetings is considered preliminary until published in a peer-reviewed medical journal.
More information
The U.S. National Library of Medicine has more about Alzheimer’s disease.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.